# A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

> **NCT03170518** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 171 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Canagliflozin 100 mg
- **DRUG:** Canagliflozin 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03170518
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-21
- **Primary completion:** 2023-09-20
- **Final completion:** 2023-09-20
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03170518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03170518, "A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03170518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*